By Daniella Parra
Creyon Bio, Inc. said it is using AI to engineer treatments for rare and common diseases.
The platform’s ability to predict and mitigate safety concerns signifies a promising advancement as they customized a treatment within a year, demonstrating reduced seizures and improved developmental milestones in a patient, it said in a statement.
“These results illustrate a key pillar of our approach – to engineer drugs for safety for rare and common diseases faster and more efficiently compared to traditional drug discovery techniques,” said Creyon CEO Chris Hart. “We developed predictive models that guide our molecular engineering from the outset and help mitigate potential safety concerns. ”
Contact:
